CompletedPhase 2NCT00794508
MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID
Studying T-B+ severe combined immunodeficiency due to gamma chain deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Donald B. Kohn, M.D.
- Principal Investigator
- Donald B. Kohn, M.D.University of California, Los Angeles
- Intervention
- ADA gene transfer(biological)
- Enrollment
- 10 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2008 – 2015
Study locations (1)
- University of California, Los Angeles, Los Angeles, California, United States
Collaborators
FDA Office of Orphan Products Development · National Institutes of Health (NIH)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00794508 on ClinicalTrials.govOther trials for T-B+ severe combined immunodeficiency due to gamma chain deficiency
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03597594Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)St. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT03538899Autologous Gene Therapy for Artemis-Deficient SCIDUniversity of California, San Francisco
- RECRUITINGPHASE1NCT03311503Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan ConditioningDavid Williams
- RECRUITINGNCT00055172Genetic Basis of ImmunodeficiencyNational Heart, Lung, and Blood Institute (NHLBI)
See all trials for T-B+ severe combined immunodeficiency due to gamma chain deficiency →